Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Granuloma, Plasma Cell × ceritinib × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 Plasma cell 1 Lymphoid 1 CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 7 Neoplasms 3 Neuroblastoma 2 Lung Neoplasms 2 Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) 1 Rhabdomyosarcoma 1 Pancreatic Neoplasms 1 Melanoma 1 Lymphoma, Large-Cell, Anaplastic 1 Granuloma, Plasma Cell 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01742286 2020-06-09

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

Novartis

Phase 1 Completed

83 enrolled 30 charts

CNSLymphoidPlasma cellSarcoma

Granuloma, Plasma Cell, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡